These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 28295767)

  • 1. Response to: HPV vaccine and autoimmunity Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.
    Hawkes D; Wilkinson W; Dunlop RA
    J Intern Med; 2017 May; 281(5):530-531. PubMed ID: 28295767
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the editor - HPV vaccine and autoimmunity Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.
    Dahan S; Shoenfeld Y
    J Intern Med; 2017 Mar; 281(3):313-315. PubMed ID: 27864851
    [No Abstract]   [Full Text] [Related]  

  • 3. Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study.
    Grönlund O; Herweijer E; Sundström K; Arnheim-Dahlström L
    J Intern Med; 2016 Dec; 280(6):618-626. PubMed ID: 27478093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
    MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.
    Muñoz N; Manalastas R; Pitisuttithum P; Tresukosol D; Monsonego J; Ault K; Clavel C; Luna J; Myers E; Hood S; Bautista O; Bryan J; Taddeo FJ; Esser MT; Vuocolo S; Haupt RM; Barr E; Saah A
    Lancet; 2009 Jun; 373(9679):1949-57. PubMed ID: 19493565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule.
    Germar MJ; Purugganan C; Bernardino MS; Cuenca B; Chen YC; Li X; Van Kriekinge G; Lee IH
    Hum Vaccin Immunother; 2017 May; 13(5):1158-1166. PubMed ID: 28075249
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma.
    Herweijer E; Leval A; Ploner A; Eloranta S; Simard JF; Dillner J; Netterlid E; Sparén P; Arnheim-Dahlström L
    JAMA; 2014 Feb; 311(6):597-603. PubMed ID: 24519299
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human papillomavirus vaccination and risk of autoimmune diseases: A large cohort study of over 2million young girls in France.
    Miranda S; Chaignot C; Collin C; Dray-Spira R; Weill A; Zureik M
    Vaccine; 2017 Aug; 35(36):4761-4768. PubMed ID: 28750853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study.
    Herweijer E; Sundström K; Ploner A; Uhnoo I; Sparén P; Arnheim-Dahlström L
    Int J Cancer; 2016 Jun; 138(12):2867-74. PubMed ID: 26856527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
    McCormack PL; Joura EA
    BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human papilloma virus vaccination in Nepal: an initial experience in Nepal.
    Singh Y; Shah A; Singh M; Verma S; Shrestha BM; Vaidya P; Nakarmi RP; Shrestha SB
    Asian Pac J Cancer Prev; 2010; 11(3):615-7. PubMed ID: 21039025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cytology and DNA HPV-testing in the era of HPV-vaccine].
    Spaczyński M; Malkowska-Walczak B; Nowak-Markwitz E
    Ginekol Pol; 2007 Sep; 78(9):696-700. PubMed ID: 18159823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Burden of disease associated with cervical cancer in malaysia and potential costs and consequences of HPV vaccination.
    Aljunid S; Zafar A; Saperi S; Amrizal M
    Asian Pac J Cancer Prev; 2010; 11(6):1551-9. PubMed ID: 21338196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan.
    Dasbach EJ; Insinga RP; Yang YC; Pwu RF; Lac C; Elbasha EH
    Asian Pac J Cancer Prev; 2008; 9(3):459-66. PubMed ID: 18990021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the relationship between human papilloma virus vaccine and autoimmune diseases.
    Pellegrino P; Carnovale C; Pozzi M; Antoniazzi S; Perrone V; Salvati D; Gentili M; Brusadelli T; Clementi E; Radice S
    Autoimmun Rev; 2014 Jul; 13(7):736-41. PubMed ID: 24468416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of HPV vaccination in Belize.
    Walwyn L; Janusz CB; Clark AD; Prieto E; Waight E; Largaespada N
    Vaccine; 2015 May; 33 Suppl 1():A174-81. PubMed ID: 25919158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States.
    Seeger JD; Amend KL; Turnbull BR; Zhou L; Marks MA; Velicer C; Saddier P
    Vaccine; 2023 Mar; 41(11):1826-1833. PubMed ID: 36424257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moving forward: human papillomavirus vaccination and the prevention of cervical cancer.
    Vetter KM; Geller SE
    J Womens Health (Larchmt); 2007 Nov; 16(9):1258-68. PubMed ID: 18001182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the nonavalent HPV vaccine in individuals previously fully or partially vaccinated with bivalent or quadrivalent HPV vaccines.
    Van Damme P; Bonanni P; Bosch FX; Joura E; Kjaer SK; Meijer CJ; Petry KU; Soubeyrand B; Verstraeten T; Stanley M
    Vaccine; 2016 Feb; 34(6):757-61. PubMed ID: 26772631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
    Grimaldi-Bensouda L; Guillemot D; Godeau B; Bénichou J; Lebrun-Frenay C; Papeix C; Labauge P; Berquin P; Penfornis A; Benhamou PY; Nicolino M; Simon A; Viallard JF; Costedoat-Chalumeau N; Courcoux MF; Pondarré C; Hilliquin P; Chatelus E; Foltz V; Guillaume S; Rossignol M; Abenhaim L;
    J Intern Med; 2014 Apr; 275(4):398-408. PubMed ID: 24206418
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.